Posso Agustin N, Mustoe Audrey, Neira Manuela, Tobin Micaela, Yamin Mohammed, Raquepo Tricia, Escobar-Domingo Maria J, Karinja Sarah J, Lee Bernard T
Division of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
J Clin Med. 2025 Aug 13;14(16):5734. doi: 10.3390/jcm14165734.
: Tissue expander (TE)-based breast reconstruction is a common procedure, but postoperative infection rates can reach up to 30%. The optimal skin antiseptic solution for minimizing these infections remains uncertain. This retrospective cohort study aimed to compare the impact of chlorhexidine and povidone-iodine for skin antisepsis in preventing surgical site infections in patients who underwent TE-based breast reconstruction. : The TriNetX database was queried to identify patients who underwent TE-based breast reconstruction. Patients were classified into two cohorts: the chlorhexidine group and the povidone-iodine group. A propensity score matching analysis was performed to control infection risk factors. The primary outcome was the occurrence of surgical site infections, while secondary outcomes included wound dehiscence, emergency department visits, debridement, and TE removal. All outcomes were assessed at 30, 60, and 90 days following surgery. : After matching of both the chlorhexidine cohort and povidone-iodine cohort, each consisted of 1446 patients. Within 30 days post-surgery, no significant differences were observed between the chlorhexidine and povidone-iodine groups in terms of the risk of surgical site infections (RR 0.62, = 0.168), wound dehiscence (RR 1.00, = 1.000), emergency department visits (RR 0.95, = 0.700), debridement (RR 0.71, = 0.271), or TE removal (RR 0.84, = 0.335). Similar results were seen at 60 and 90 days post-surgery. : This study suggests that chlorhexidine and povidone-iodine may be equally effective for skin antisepsis in preventing surgical site infections and associated complications in patients undergoing TE-based breast reconstruction.
基于组织扩张器(TE)的乳房重建是一种常见的手术,但术后感染率可达30%。用于将这些感染降至最低的最佳皮肤消毒溶液仍不确定。这项回顾性队列研究旨在比较洗必泰和聚维酮碘用于皮肤消毒对接受基于TE的乳房重建患者预防手术部位感染的影响。
查询TriNetX数据库以识别接受基于TE的乳房重建的患者。患者被分为两个队列:洗必泰组和聚维酮碘组。进行倾向评分匹配分析以控制感染风险因素。主要结局是手术部位感染的发生,次要结局包括伤口裂开、急诊就诊、清创和TE移除。所有结局均在术后30、60和90天进行评估。
在洗必泰队列和聚维酮碘队列匹配后,每组各有1446例患者。术后30天内,洗必泰组和聚维酮碘组在手术部位感染风险(RR 0.62,P = 0.168)、伤口裂开(RR 1.00,P = 1.000)、急诊就诊(RR 0.95,P = 0.700)、清创(RR 0.71,P = 0.271)或TE移除(RR 0.84,P = 0.335)方面均未观察到显著差异。术后60天和90天也出现了类似结果。
本研究表明,洗必泰和聚维酮碘在预防接受基于TE的乳房重建患者的手术部位感染及相关并发症方面,可能在皮肤消毒方面同样有效。